Ar­cutis show­cas­es pos­i­tive PhI­II da­ta show­ing its top­i­cal cream scratched the sweet spot Ote­zla or steroids could­n't

The goal at Ar­cutis Bio­ther­a­peu­tics $AR­QT had been clear and straight­for­ward from day 1: to prove that it can take ex­ist­ing com­pounds against well es­tab­lished der­ma­tol­ogy tar­gets and make re­for­mu­la­tions that hit a sweet spot not yet scratched by any of its myr­i­ad block­buster, gener­ic or ex­per­i­men­tal ri­vals.

The first proof came Mon­day in the form of pos­i­tive topline re­sults from a pair of piv­otal Phase III tri­als. In­vestors re­act­ed cheer­ful­ly, send­ing the stock up 28.14% to $34.97.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER